Raphael Pharmaceutical (RAPH) Retained Earnings (2020 - 2026)

Raphael Pharmaceutical has disclosed Retained Earnings across 7 years of filings, most recently posting -$10.6 million for Q2 2026.

• In Q2 2026, Retained Earnings fell 10.17% year-over-year to -$10.6 million; the TTM figure through Jun 2026 stood at -$10.6 million (down 10.17% YoY), while the FY2025 annual figure was -$10.2 million, down 14.39% from the prior year.
• Retained Earnings came in at -$10.6 million for Q2 2026 at Raphael Pharmaceutical, down from -$10.2 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $4.9 million in Q3 2022 to a low of -$10.6 million in Q2 2026.
• Average Retained Earnings over 5 years is -$6.5 million, with a median of -$7.9 million recorded in 2024.
• Year-over-year, Retained Earnings soared 334.27% in 2022 and tumbled 292.79% in 2023.
• Over 5 years, Retained Earnings stood at -$6.0 million in 2022, then dropped by 22.3% to -$7.4 million in 2023, then declined by 20.61% to -$8.9 million in 2024, then decreased by 14.39% to -$10.2 million in 2025, then slipped by 4.45% to -$10.6 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$10.6 million in Q2 2026, -$10.2 million in Q4 2025, and -$9.9 million in Q3 2025.